Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Shares Outstanding (Weighted Average) (2016 - 2025)

Angiodynamics (ANGO) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $41.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.52% year-over-year to $41.5 million, compared with a TTM value of $41.5 million through Nov 2025, up 1.52%, and an annual FY2025 reading of $40.9 million, up 1.67% over the prior year.
  • Shares Outstanding (Weighted Average) was $41.5 million for Q4 2025 at Angiodynamics, up from $41.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $41.5 million in Q4 2025 and bottomed at $38.3 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $39.8 million, with a median of $39.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 0.87% in 2022, then rose 2.23% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $39.1 million in 2021, then increased by 0.87% to $39.4 million in 2022, then grew by 1.61% to $40.0 million in 2023, then increased by 2.23% to $40.9 million in 2024, then rose by 1.52% to $41.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ANGO at $41.5 million in Q4 2025, $41.2 million in Q3 2025, and $40.9 million in Q2 2025.